2020 Annual Report

#TEAMGENEVA

A Message from the President & CEO

ELISE HUSZAR, MBA

2020 ANNUAL REPORT LETTER FROM THE PRESIDENT & CEO

For 27 years, The Geneva Foundation’s history has been filled with achievements and challenges that have driven innovative thinking and powerful military medical research around the world, shaping us into the organization we are today.

Geneva’s long-term success is, in part, due to a disciplined management approach that prioritizes flexibility as we address the world’s most pressing healthcare needs. 2020 was no different in that regard – but 2020 will be long remembered as a defining moment in Geneva’s history. The events of the past year presented obstacles of a magnitude that were impossible to predict, as we responded to the myriad of challenges associated with the global COVID-19 pandemic, among other national societal issues. However, 2020 also created new opportunities for Geneva, as we pivoted to respond to and address the needs and expectations of our employees, military partners, research teams, and key stakeholders.

The COVID-19 pandemic brought to the forefront the importance of prioritizing our individual and collective health, and the commitment we’ve made to support the medical research needs of the Department of Defense. I am immensely proud of Geneva’s ability to respond quickly to these challenges and build upon them as we plan for the future.

Geneva’s participation in Operation Warp Speed presented an incredibly unique opportunity for the organization, as we mobilized our vast clinical trials expertise and network of military treatment facilities in the execution of two global vaccine clinical trials. True to form, Geneva was able to rapidly advance and operationalize clinical trials at six military treatment facilities nationwide, recruit and hire over 100 highly skilled and technical personnel to support the trials, procure over 17,000 items in support, all while meeting regulatory requirements within the accelerated timeline. The pace and scope of this complex and momentous effort is unprecedented and could not have been accomplished without our incredible employees and research teams.

Geneva was also part of a team selected to lead an effort to address the urgent needs to expand telehealth services and critical care resources to every bedside. COVID-19 highlighted a critical problem to address – the shortage of critical care trained clinicians. The National TeleCritical Care Network (NETCCN) for COVID-19 is an example of what can happen when we leverage existing partnerships for the greater good.

COVID-19 aside, it was a transformative year in several other areas of military medicine. Geneva researchers working with the Post-Traumatic Stress Disorder (PTSD) Biology Consortium uncovered distinct biotypes for PTSD, the first of any kind for any psychological disorder, shedding light on better screening tools for combat veterans. The USU-4D Bio3 Center for Biotechnology (4DBio3), managed by Geneva, launched the On-Demand Blood program and conducted a successful 3D-bioprinting mission in space. The Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) program, launched in 2019, has already enrolled over 1,000 patients across 12 rehabilitative medicine studies, and streamlined 11 musculoskeletal injury protocols across three branches of the military.

Geneva enters 2021 with a focused Board of Directors, engaged Scientific Advisory Board, and over 500 dedicated employees who are ready to tackle the next set of challenges. As the events of 2020 have proven, we know that together, we can do amazing things. We are equally appreciative of our donors whose support enables us to further grow our capabilities and inspire young, novice researchers to pursue their passions.

This report illustrates Geneva’s efforts to advance military medicine around the world for the global community and spotlights our teamwork in action. We are grateful for your ongoing support of Geneva’s mission.

Sincerely,

Elise W. Huszar, MBA
President and Chief Executive Officer

Geneva Fights COVID-19

2020 has demonstrated the critical importance of military medicine in shaping positive global health outcomes. Since the onset of the COVID-19 pandemic, Geneva researchers and employees have been relentless in pursuit of vaccines, treatments, therapeutics, and other novel solutions to address one of the most scientific challenges of our lifetime.

Read More

2020 At A Glance

2020 Top 15 Research Programs By Funding

2020 Notable Achievements

February

Geneva launches the USU-4DBio3 Center for Biotechnology (USU-4DBio3 Center) On-Demand Blood Program to deliver on-demand blood and revolutionize military trauma care. This adaption for use near the point-of-need is a game-changer.

READ MORE

March

Geneva researchers John M. Dye, PhD and Andrew Herbert, PhD of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), along with their team, develop the first-ever experimental antibody treatment that protects from Sudan virus.

READ MORE

April

Geneva hosts the first-ever Post-Operative Rehabilitation Meeting to standardize 13 musculoskeletal injury protocols for the Army, Navy, and Air Force. This significant meeting was made possible by the support of the Broussard Family Foundation.

READ MORE

In partnership with USU, TechShot, Inc, and nScrypt, Geneva successfully completes the first 3D printing test experiment of a human knee meniscus onboard the International Space Station U.S. National Laboratory.

READ MORE

May

The Food and Drug Administration (FDA) issues an Emergency Use Authorization for Vekliry (remdesivir) for the treatment of hospitalized patients with severe coronavirus disease. Geneva researcher and employee Travis Warren, PhD and his colleagues are among the first scientists to run early tests on remdesivir as a treatment for Ebola virus.

READ MORE

Geneva receives a subaward for an expanded phase of the CARE Consortium. As part of the NCAA-DoD Grand Alliance, it is the largest study in history of concussion and repetitive head injuries with the goal to identify ways to improve diagnosis, treatment, and prevention.

READ MORE

The FDA authorizes emergency use of the COVID-19 Airway Management Isolation Chamber (CAMIC) within the military for use by healthcare providers to protect against exposure to airborne particulates during transport of COVID-19 patients. The CAMIC was developed by a team of Army doctors including Geneva researcher MAJ (P) Douglas Ruhl, MD, MSPH at Madigan Army Medical Center.

READ MORE

June

Under Principal Investigator LTC Christopher J. Colombo, MD at Madigan Army Medical Center, a Geneva team is selected to rapidly develop and deploy a National Telecritical Care Network (NETCCN) for COVID-19 to bring critical care resources to every bedside.

READ MORE

September

Geneva is selected as a sub under prime contract research organization (CRO) Pharm-Olam to administer phase III clinical trials at six military treatment facilities for two lead COVID-19 vaccine candidates being developed under Operation Warp Speed (OWS). OWS is a public-private partnership to deliver safe and effective doses of a COVID-19 vaccine by January 2021.

READ MORE

October

With the addition of 4,037 square feet at its offsite facility to support the On-Demand Blood program, the USU-4D Bio3 Center facility expands to 10,267 square feet and includes a biofabrication suite, tissue culture room, bioreactor and sensor facility, biotechnology incubator suite, medical/surgical simulation room, and distance education and training facility.

READ MORE

November

Andriy Batchinsky, MD is awarded Geneva’s Researcher of the Year. As a leader in military medicine, Dr. Batchinsky is pioneering new treatments for trauma care and lung injuries both on and off the battlefield.

READ MORE

December

Geneva Principal Investigator Sheli Radoshitzsky, PhD at USAMRIID, et al., demonstrates proof of concept for an immunotoxin-based targeted killing of infected cells as a potential antiviral intervention for the Ebola virus.

READ MORE

At the Heart of Geneva is Our Employees

With a record number of new hires added, including over 115 employees to support Operation Warp Speed, Geneva employed over 550 people worldwide at the end of 2020. We are tremendously grateful for the dedication and resilience of our team, who quickly pivoted  to address the many challenges presented during the COVID-19 pandemic.

New Hires

Highly Skilled and Technical Employees in the Field

Geneva employs over 460 highly-skilled and technical research professionals at 50+ performance sites across the world. Geneva’s experience in hiring and retaining a variety of these positions proved to be invaluable as the urgent needs of COVID-19 research were felt across the organization.

Geneva’s Wave the Flag Recipients

Geneva recognizes excellence in employees who go above and beyond the normal scope of their work, demonstrate Geneva’s core values, and strengthen our mission of promoting and supporting the advancement of military medicine. The Wave the Flag award is presented quarterly to an employee who exceeds expectations and exhibits Geneva’s core values.

Donor Impact

Philanthropy Makes a Difference

Geneva donors make an impact in advancing critical research and the opportunity for revolutionary change on a global scale. By contributing to Geneva, donors directly support researchers in their pursuit of discovery and innovation in military medicine beyond the reaches of federal research dollars.

The Discovery Fund: 2020 Impact

Geneva’s Discovery Fund allows unrestricted donor contributions to be directed towards pressing research initiatives in real-time.  This pool of flexible dollars infuses innovation into existing research programs, enables our scientists to respond to urgent needs, amplifies the voices of novice researchers, supports pilot and proof-of-concept research, and leverages cross-sectoral partnerships. Some programs supported by The Discovery Fund include:

Responding to Critical Medical Issues in Real-Time

COVID-19 Support

In partnership with the MIRROR program, Geneva supplied COVID-19 Antibody Test Kits to a military treatment facility, providing researchers additional tools outside of federal funding.

Thank you to the Broussard Family Foundation for your generous support.

READ MORE

Leveraging Existing Partnerships to Increase Innovation

MIRROR Tri-Service Post-Operative Rehabilitation Meeting

Geneva brought together more than 50 military leaders and scientific experts within the physical therapy, orthopedics, physical medicine, and pain management fields for the first-ever Tri-Service Post-Operative Rehabilitation Protocol Consensus Meeting to standardize disparate protocols for military healthcare.

Thank you to the Broussard Family Foundation for your generous support.

READ MORE

Advancing Nursing Research to Support Military Healthcare

Jonas-Geneva Scholar CDR Melissa Troncoso, MSN, NP-C, CHWC

The Jonas-Geneva Scholarship is a partnership between Jonas Philanthropies and Geneva to support doctoral nursing candidates engaged in veteran and military medical research. In 2020, recipient Navy Commander (CDR) Melissa Troncoso, MSN, NP-C, CHWC finalized her research in a recently published manuscript, “Targeting Nutritional Fitness by Creating a Culture of Health in the Military” that was featured in Military Medicine.

READ MORE

Pilot Research with a Local Impact

The JBLM Small Grant Competition

In 2019, Geneva held the first-ever small grant competition for researchers at Joint Base Lewis McChord. Award recipients LTC (P) Matthew Eckert MD, FACS and CAPT Daniel Lammers, MD piloted research on "Combatting Ischemia Reperfusion Injury from Traumatic Injury Requiring Occlusion of the Aorta via Adenosine, Lidocaine, and Magnesium (ALM)." Following the obtainment of data from this initial award, the team was awarded a larger grant for a follow-on study.

Thank you to the LT Murray Family Foundation for your generous support.

READ MORE

Research Accomplishments

Progress in Areas of Critical and Global Importance

Geneva advances complex research programs by developing and executing successful strategies that deliver solutions to the DoD and medical community. While 2020 presented some challenges, initially affecting some clinical trials and laboratory facilities, operations were able to move forward as new safeguards were put back into place. Some highlights over 2020 are featured below.

Inspiring Researchers

Military medicine has led to key advancements in areas including biotechnology, trauma care, human performance, rehabilitative medicine, and infectious diseases. We recognize and honor our inspiring researchers and research teams, who are leading the way in pursuing innovative solutions that impact military and global populations.

Top Five Largest Awards

Geneva’s top five largest awards funded in 2020 totaled $48M.

On-Demand Blood Program

Principal Investigator: Dr. Vincent Ho
Site: Uniformed Services University
Funding Source: Uniformed Services University

Operation Warp Speed

Sites: Brooke Army Medical Center, Fort Belvoir Community Hospital, Navy Medical Center San Diego, Wilford Hall Ambulatory Surgical Center, Womack Army Medical Center
Funding Source: Uniformed Services University

Service Academy Longitudinal mTBI Outcomes Study

Principal Investigators: Dr. Kenneth Cameron, Dr. Gerald McGinty
Sites: Keller Army Community Hospital, US Air Force Academy Hospital
Funding Source: Uniformed Services University

Survivability Criteria and Vital Organ Injury Metrics for Whole Body When Exposed to Extreme Blast

Principal Investigator: Dr. Venkatasivasai Sujith Sajja
Site: Walter Reed Army Institute of Research
Funding Source: 59th Medical Wing Department of Emergency Medicine

Novel Immunotherapy for Traumatic Hemorrhage

Principal Investigator: Dr. Yansong LI
Site: U.S. Army Institute of Surgical Research
Funding Source: CDMRP Peer Reviewed Medical Research Program

Performance Sites

In 2020, Geneva supported over 315 research programs at over 50 military treatment facilities and federal laboratories worldwide.

Armed Forces Research Institute of Medical Sciences

Bangkok, Thailand

David Grant Medical Center

California

Marine Corps Air Station Miramar Branch Health Clinic

California

Naval Health Research Center

California

Naval Hospital Camp Pendleton

California

Naval Hospital Twentynine Palms

California

Navy Medical Center San Diego

California

Evans Army Community Hospital

Colorado

U.S. Air Force Academy Hospital

Colorado

Navy Trauma Training Center

Florida

Centers for Disease Control and Prevention

Georgia

Eisenhower Army Medical Center

Georgia

Telemedicine and Advanced Technology Research Center – Mobile Health Innovation Center

Georgia

Tripler Army Medical Center

Hawaii

Landstuhl Regional Army Medical Center

Landstuhl, Germany

Malcolm Grove Medical Center

Maryland

Military Operational Medicine Research Program

Maryland

National Cancer Institute

Maryland

Naval Medical Research Center

Maryland

Telemedicine and Advanced Technology Research Center

Maryland

U.S. Army Medical Research and Development Command

Maryland

U.S. Army Medical Research Institute of Chemical Defense

Maryland

U.S. Army Medical Research Institute of Infectious Diseases

Maryland

Uniformed Services University

Maryland

Walter Reed Army Institute of Research

Maryland

Walter Reed National Military Medical Center

Maryland

Nellis Air Force Base

Nevada

Keller Army Community Hospital

New York

Naval Hospital Camp Lejeune

North Carolina

Womack Army Medical Center

North Carolina

Wright Patterson Air Force Base

Ohio

Brooke Army Medical Center

Texas

Regional Health Command Central

Texas

U.S. Army Institute of Surgical Research

Texas

US Army Medical Center of Excellence

Texas

Wilford Hall Medical Center

Texas

William Beaumont Army Medical Center

Texas

Fort Belvoir Community Hospital

Virginia

Naval Medical Center Portsmouth - VA

Virginia

Madigan Army Medical Center

Washington

Federal Aviation Administration

Washington, D.C.

Sponsors & Collaborators

A word of thanks to our sponsors and collaborators – we are committed to our partnerships and grateful for your support.

AbbVie

AbCellera Biologics Inc.

Acerta Pharma, LLC.

Admiab, LLC

Advanced Bioprocess Systems

Advanced Technology International

Albert Einstein College of Medicine

Allergan PLC

Altor Bioscience Corporation

Amgen Inc

Applied Research Associates, Inc.

Arena

AstraZeneca

Athens Orthopedic Clinic

BeiGene USA, Inc.

BioCryst Pharmaceuticals, Inc.

Biomojo

BioFactura

Bristol-Myers Squibb Co.

Celdara Medical

Celgene Corporation

Centers for Disease Control and Prevention

CEPI

Childrens Oncology Group

Cofactor Genomics, Inc

Conatus Pharmaceuticals, Inc.

Congressionally Directed Medical Research Programs

Continuous Precision Medicine

Council of the Queensland Institute of Medical Research

CSL Behring LLC

Daiichi Sankyo

Defense Advanced Research Projects Agency

Defense Threat Reduction Agency

Department of Veterans Affairs

Deverra Therapeutics

Diomics Corporation Inc.

DocBox

Duke University

Echosens

Emory University

Eunice Kennedy Shriver National Institute of Fetal Medicine Units Network

Epicentrx

Evrys Bio

Exact Sciences

Exonicus, Inc

Ferring

Ferring Pharmaceuticals

Fraunhofer

Galera Therapeutics, Inc.

Game Ready

GE Healthcare

Genentech, Inc

Genfit Corporation

George Washington University

GeoVax, Inc.

Gilead Sciences, Inc.

H. Lee Moffitt Cancer Center and Research Institute

Halyard Health

Hamilton Health Sciences

Henry Jackson Foundation

High Point University

HighTide Therapeutics USA, LLC.

Inovio Pharmaceuticals, Inc.

Institute National de Recherche Biomedicale

Integrated Bio Therapeutics

Intercept Pharmaceuticals, Inc

International Space Station U.S. National Laboratory

Irving Burton Associates

Janssen Therapeutics

Johns Hopkins University

Kennell and Associates, Inc

Kessler Foundation

Kura Oncology, Inc.

Leidos, Inc.

Lipogems

Madrigal Pharmaceuticals, Inc

Mapp BioPharmaceutical, Inc.

Mass General

Mayo Clinic

Medpace, Inc.

Microbiotix

Mimedx

nScrypt

Natick Contracting Division

National Cancer Institute

National Institute of Allergy and Infectious Diseases

National Institutes of Health

New Jersey Regenerative Institute

NGM Biopharmaceuticals

Nonin Medical Clinic, Inc.

NorthSea

Novartis Pharmaceuticals Corporation

Novavax

Novocure

Now Diagnostics, Inc.

OMB Innovations

Omnicure

Parexel International Corporation

Pfizer

Pharm-Olam, LLC

Pharpoint Research

Phillips Healthcare

Purdue University

Regeneron Pharmaceuticals, Inc

RoosterBio

SAB Biotheraputics, Inc.

Safi Biosolutions

Society of Critical Care Medicine

Sciperio

Seres

Sonex Health

Special Operations Command

Spectrum Pharmaceuticals

Stanford University

State University of New York - Stony Brook University

SWIU

Symbient Product Development

Telemedicine & Advanced Technology Research Center

Tech Shot, Inc

Texas A&M University

Texas Tech University Health Sciences Center

TG Therapeutics

Theradaptive

Thomas Jefferson University

Tobira Therapeutics, Inc.

TriService Nursing Research Program

U.S. Army Medical Research Acquisition Activity

U.S. Army Medical Research and Development Command

U.S. Army Medical Research and Material Command

U.S. Army Medical Research Institute of Infectious Diseases

Uniformed Services University

University of Florida

University of Iowa

University of Maryland

University of Miami

University of Minnesota

University of North Carolina

University of San Francisco

University of South Alabama

University of Texas at Austin

University of Virginia

University of Washington

US Army Medical Research Acquisition Activity

US Army Research Lab - Orlando

UWCREST

Vapotherm

Wayne State University

Western Michigan University

Xcovery Holdings, Inc

zCore Business Solutions, Inc.

Zydus

Financials

Geneva continued to deliver strong performance in 2020 with a total revenue of $67.1M.

 

Statement of Revenue & Expenditures

2018

2019

2020

(Rounded to the nearest thousand)

 

 

 

Total Grant, Contract, and Other Award Revenue

$51,791,217

$55,938,475

$67,110,553

Grant

$26,976,833

$31,636,422

$46,734,995

Contract

$21,992,580

$21,899,095

$18,568,628

Other Award Revenue

$2,821,804

$2,402,958

$1,806,930

 

 

 

Program Expenses

$42,440,761

$47,892,929

$56,977,675

 

 

 

Net Income from Grants, Contracts, and Awards

$9,350,456

$8,045,546

$10,132,878

 

 

 

Support Services

 

 

 

General and Administrative

$8,337,542

$8,240,252

$8,268,505

Fund Development

$99,346

$100,953

$73,830

Total Support Services

$8,436,888

$8,341,205

$8,342,335

 

 

 

Total Other Income (Loss)

($54,297)

$78,342

$79,675

 

 

 

Increase (decrease) in net assets

$859,271

($217,317)

$1,870,218

 

 

 

Unrestricted Net Assets

 

 

 

Beginning of Year

$3,911,272

$4,770,543

$4,553,226

End of Year

$4,770,543

$4,553,226

$6,423,444